Pharvaris N.V. (PHVS) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 36.2% versus a loss of 2.0%. Over five years, PHVS leads with a +96.8% price change compared with +69.9% for PTCT. PTC Therapeutics is the larger company by market cap ($5.40 billion vs $2.18 billion), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHVS | PTCT |
|---|---|---|
| Share price | $31.10 | $64.70 |
| Market cap | $2.18B | $5.40B |
| 1-day change | -0.06% | +3.42% |
| YTD return | +12.07% | -14.82% |
| 1-year return | +36.16% | -1.98% |
| 5-year return | +96.84% | +69.86% |
| Forward P/E | — | 27.30 |
| EPS (TTM) | $-3.06 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.73B |
| Revenue growth (YoY) | — | +114.51% |
| Net income (latest FY) | $-25.99M | $682.64M |
| Operating margin | — | 50.09% |
| Net margin | — | 39.44% |
| 52-week high | $43.25 | $90.87 |
| 52-week low | $20.65 | $61.23 |
| Distance from 52-week high | -28.09% | -28.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +84.47% | +56.21% |
| Average volume | 711.75K | 1.14M |
| Shares outstanding | 70.20M | 83.46M |
| Employees | 148 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTC Therapeutics is about 2.5 times larger than Pharvaris N.V. by market value ($5.40B vs $2.18B).
- PHVS has outperformed PTCT by 38.1 percentage points over the past year.
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
PHVS vs PTCT FAQ
Which is bigger, Pharvaris N.V. or PTC Therapeutics?
PTC Therapeutics (PTCT) is larger, with a market capitalization of $5.40B compared with $2.18B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, PHVS or PTCT?
PHVS returned +36.16% over the past 12 months, compared with -1.98% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Pharvaris N.V. and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.